Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CTLT

CTLT - Catalent Inc Stock Price, Fair Value and News

57.93USD-0.06 (-0.10%)Market Closed

Market Summary

CTLT
USD57.93-0.06
Market Closed
-0.10%

CTLT Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

CTLT Stock Price

View Fullscreen

CTLT RSI Chart

CTLT Valuation

Market Cap

10.5B

Price/Earnings (Trailing)

-9.84

Price/Sales (Trailing)

2.54

EV/EBITDA

-15.04

Price/Free Cashflow

-74.89

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

-30.04%

Return on Equity

-22.32%

Return on Assets

-10.14%

Free Cashflow Yield

-1.34%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

3.57%

Rev. Growth (Qtr)

4.88%

CTLT Earnings

Earnings (TTM)

-1.1B

Earnings Growth (Yr)

100%

Earnings Growth (Qtr)

100%

Breaking Down CTLT Revenue

Last 7 days

0.6%

Last 30 days

5.2%

Last 90 days

4.4%

Trailing 12 Months

21.8%

How does CTLT drawdown profile look like?

CTLT Financial Health

Current Ratio

2.66

Debt/Equity

1.03

Debt/Cashflow

0.05

CTLT Investor Care

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

-6.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.1B000
20234.5B4.3B4.2B4.1B
20224.7B4.8B4.8B4.7B
20215.9B4.0B4.2B4.5B
20202.9B5.2B5.4B5.6B
20192.5B2.5B2.6B2.7B
20182.4B2.5B2.5B2.5B
20172.0B2.1B2.2B2.3B
20161.8B1.8B1.9B1.9B
20151.8B1.8B1.8B1.8B
20141.8B1.8B1.8B1.8B
20131.8B1.8B1.8B1.8B
201201.7B1.7B1.7B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Catalent Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 08, 2024
masanovich matti
sold
-169,823
56.74
-2,993
svp, chief financial officer
Jun 04, 2024
hopson ricky
sold
-76,022
54.2631
-1,401
pres. bioproduct delivery, cos
Mar 15, 2024
gunther scott
sold
-21,749
56.2
-387
svp, quality & reg. affairs
Jan 25, 2024
kreuzburg christa
sold (taxes)
-26,364
50.41
-523
-
Jan 16, 2024
hatzfeld michael
acquired
-
-
7,908
chief accounting officer
Dec 08, 2023
hopson ricky
sold (taxes)
-9,518
37.18
-256
pres. clinical dev supply div
Dec 08, 2023
maselli alessandro
acquired
-
-
3,761
president & ceo
Dec 08, 2023
gennadios aristippos
acquired
-
-
1,505
group pres. pharma & consumer
Dec 08, 2023
hopson ricky
acquired
-
-
747
pres. clinical dev supply div
Dec 08, 2023
gunther scott
acquired
-
-
1,023
svp, quality & reg. affairs

1–10 of 50

Which funds bought or sold CTLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
China Universal Asset Management Co., Ltd.
unchanged
-
-1,386
354,305
0.05%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
reduced
-7.4
-41,500
492,912
0.03%
Jul 19, 2024
HARBOR INVESTMENT ADVISORY, LLC
unchanged
-
-10.00
2,643
-%
Jul 19, 2024
Venturi Wealth Management, LLC
added
337
10,222
13,271
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
sold off
-100
-246,630
-
-%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-7.79
-1,949,540
21,982,800
0.02%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
1.71
8,020
619,261
-%
Jul 19, 2024
First Horizon Advisors, Inc.
reduced
-50.08
-36,213
35,817
-%
Jul 19, 2024
CENTRAL BANK & TRUST CO
unchanged
-
-5.00
1,124
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
added
29.15
109,286
490,832
-%

1–10 of 50

Are Funds Buying or Selling CTLT?

Are funds buying CTLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CTLT
No. of Funds

Unveiling Catalent Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2024
capital world investors
5.3%
9,656,560
SC 13G/A
Feb 14, 2024
t. rowe price investment management, inc.
6.2%
11,209,374
SC 13G/A
Feb 14, 2024
nomura holdings inc
6.4%
11,487,158
SC 13G
Feb 13, 2024
janus henderson group plc
7.3%
13,249,339
SC 13G/A
Feb 13, 2024
vanguard group inc
11.17%
20,186,499
SC 13G/A
Feb 12, 2024
veritas asset management llp
3.58%
6,467,989
SC 13G/A
Feb 09, 2024
capital world investors
10.6%
19,113,006
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
16,175,385
SC 13G/A
Oct 10, 2023
capital world investors
10.0%
18,029,128
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
9.2%
16,578,946
SC 13G/A

Recent SEC filings of Catalent Inc

View All Filings
Date Filed Form Type Document
Jul 10, 2024
4
Insider Trading
Jul 08, 2024
144
Notice of Insider Sale Intent
Jun 05, 2024
4
Insider Trading
Jun 04, 2024
144
Notice of Insider Sale Intent
May 29, 2024
8-K
Current Report
May 16, 2024
DEFA14A
DEFA14A
May 16, 2024
8-K
Current Report
May 13, 2024
144
Notice of Insider Sale Intent
May 10, 2024
SC 13G/A
Major Ownership Report
May 08, 2024
8-K
Current Report

Peers (Alternatives to Catalent Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.68
2.44
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Catalent Inc News

Latest updates
MarketBeat10 hours ago
Yahoo Finance16 Jul 202404:28 pm
American Banking and Market News16 Jul 202412:05 pm

Catalent Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.9%1,0741,0249821,0551,0371,1491,0221,2871,2731,2171,0251,1881,0539118463,094761721665726618
Gross Profit33.9%229171169215180387258462423405324439366298249335239232178257199
  S&GA Expenses-14.4%214250205217190226196226207228183184173165165157136141143143130
EBITDA Margin17.4%-0.25*-0.30*-0.22*-0.02*0.06*0.16*0.16*0.17*0.18*0.22*0.23*----------
Interest Expenses1.5%-65.00-66.00-58.00-56.00-51.00-47.00-32.00-32.00-33.00-32.00-26.00-31.50-27.00-26.00-26.00-20.40-34.40-34.90-36.30-31.00-26.40
Income Taxes-37.5%15.0024.00-38.00-67.00-55.0033.003.0017.0035.0018.0010.0039.0085.0021.00-15.0024.009.0013.00-6.909.0011.00
Earnings Before Taxes52.7%-86.00-182-797-177-2821143.0018517611510322231710967.0017930.0059.00-6.8080.0043.00
EBT Margin14.4%-0.30*-0.35*-0.27*-0.08*0.00*0.10*0.10*0.12*0.13*0.17*0.18*----------
Net Income51.0%-101-206-759-110-22781.00-16814197.0093.0018323288.0082.0015421.0046.000.0071.0032.00
Net Income Margin10.5%-0.28*-0.32*-0.24*-0.06*0.00*0.08*0.08*0.10*0.11*0.13*0.14*----------
Free Cashflow-444.4%-62.0018.00-15458.00-20246.00-241-166-10.00-54.009.00----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Assets6.4%10,5089,8799,98810,02310,77710,83011,14810,20610,50810,32210,20310,1839,1128,7698,1987,9847,7777,0806,1956,1206,184
  Current Assets15.6%2,9172,5232,5702,6142,6922,7382,9192,6992,9173,0252,9743,9312,9182,7752,5192,3562,2931,7461,3011,2671,396
    Cash Equivalents-100.0%-1622292092802524422814497868491,9698969888331,007953608189243345
  Inventory-100.0%-742775796777744818732702676688622563528461384324297250251257
  Net PPE-100.0%-3,7353,7773,7233,6823,6713,5793,1673,1272,8202,7272,5812,5242,3592,1302,0361,9011,7701,6181,5611,537
  Goodwill-100.0%-2,3392,3512,3163,0393,0233,2152,9293,0063,0123,0262,5312,5192,5152,4622,4902,4712,4492,2082,1962,221
Liabilities-8.5%5,7336,2686,3016,1826,1666,1276,2565,5265,7335,6905,7225,8034,8384,6974,3844,3064,2714,2853,8733,8643,896
  Current Liabilities9.0%1,0981,0071,0361,5341,5301,4871,5529691,0981,0461,0451,0961,1961,1391,024920893917658616671
  Long Term Debt-100.0%-4,9334,9594,3224,3134,2614,2214,0984,1714,1574,1914,2253,1663,1502,9842,9852,9452,9272,8252,8592,883
Shareholder's Equity32.2%4,7753,6113,6873,8414,6114,7034,8924,7004,7754,6324,4814,0213,9153,7133,4563,0722,8992,1881,7161,6491,682
  Retained Earnings164.4%518-804-703-49726237261951851835020911425.00-150-377-460-535-681-694-731-723
  Additional Paid-In Capital-100.0%-4,7694,7424,7244,7014,6974,6864,6744,6494,6304,6154,2344,2054,1864,1613,9013,8183,2612,7592,7552,757
Accumulated Depreciation-100.0%-1,8421,7561,6471,5961,5401,4651,3581,3471,3081,2151,2151,179--------
Shares Outstanding-100.0%-180180180179180180180179179171171171--------
Float-----------7,900---17,710---8,200--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-89.3%12.00112-70.00196-64.00214-92.0069.0013869.0016313475.0074.0015017212212125.0088.0075.00
  Share Based Compensation6.3%17.0016.0019.00-6.0010.0019.0012.0010.0011.0021.0013.00---------
Cashflow From Investing22.1%-74.00-95.00-84.00-121-110-608-116-394-191-1,132-167-213-82.00-203-151-162-465-114-84.90-1,252-48.90
Cashflow From Financing100.0%--14.0098.00-51.00-25.0052374.001.00-3.00-49.001,082-17.00166-57.0050.00331773-66.00-35.801,284-8.70
  Buy Backs---------------1.8084.00-494----0.20
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CTLT Income Statement

2024-03-31
Consolidated Statements of Operations - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net revenue$ 1,074.0$ 1,037.0$ 3,080.0$ 3,208.0
Cost of sales845.0857.02,511.02,383.0
Gross margin229.0180.0569.0825.0
Selling, general, and administrative expenses214.0190.0669.0612.0
Goodwill, Impairment Loss0.0(210.0)(687.0)(210.0)
Other Cost and Expense, Operating32.015.068.040.0
Operating earnings(17.0)(235.0)(855.0)(37.0)
Interest expense, net65.051.0189.0130.0
Other (income)/expense, net[1]4.0(4.0)21.0(2.0)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total(86.0)(282.0)(1,065.0)(165.0)
Income tax expense15.0(55.0)1.0(19.0)
Net earnings/(loss)$ (101.0)$ (227.0)$ (1,066.0)$ (146.0)
Earnings Per Share, Basic$ (0.56)$ (1.26)$ (5.87)$ (0.81)
Earnings Per Share, Diluted$ (0.56)$ (1.26)$ (5.87)$ (0.81)
[1]Other expense, net during the three and nine months ended March 31, 2024 and 2023 primarily includes foreign currency remeasurement losses/gains.

CTLT Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 162.0$ 280.0
Trade receivables, net875.01,002.0
Inventories742.0777.0
Prepaid expenses and other744.0633.0
Total current assets2,523.02,692.0
Property, plant, and equipment, net3,735.03,682.0
Other assets:  
Goodwill2,339.03,039.0
Other intangibles, net875.0980.0
Deferred Income Tax Assets, Net66.055.0
Other Assets, Noncurrent341.0329.0
Total assets9,879.010,777.0
Current Liabilities:  
Debt, Current47.0536.0
Accounts payable377.0424.0
Other accrued liabilities583.0570.0
Total current liabilities1,007.01,530.0
Long-term obligations, less current portion4,933.04,313.0
Pension liability97.0100.0
Deferred Income Taxes64.076.0
Other liabilities167.0147.0
Total liabilities$ 6,268.0$ 6,166.0
Common Stock, Par or Stated Value Per Share$ 0.01$ 0.01
Common Stock, Shares Authorized1,000,000,0001,000,000,000
Common Stock, Value, Outstanding$ 2.0$ 2.0
Preferred Stock, Value, Outstanding0.00.0
Additional paid in capital4,769.04,701.0
Accumulated deficit(804.0)262.0
Accumulated other comprehensive income/(loss)(356.0)(354.0)
Total shareholders' equity3,611.04,611.0
Total liabilities, redeemable preferred stock, and shareholders’ equity$ 9,879.0$ 10,777.0
Common stock, shares issued (shares)181,000,000180,000,000
CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
 CEO
 WEBSITEcatalent.com
 INDUSTRYPharmaceuticals
 EMPLOYEES17800

Catalent Inc Frequently Asked Questions


What is the ticker symbol for Catalent Inc? What does CTLT stand for in stocks?

CTLT is the stock ticker symbol of Catalent Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalent Inc (CTLT)?

As of Fri Jul 19 2024, market cap of Catalent Inc is 10.48 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTLT stock?

You can check CTLT's fair value in chart for subscribers.

What is the fair value of CTLT stock?

You can check CTLT's fair value in chart for subscribers. The fair value of Catalent Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalent Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalent Inc a good stock to buy?

The fair value guage provides a quick view whether CTLT is over valued or under valued. Whether Catalent Inc is cheap or expensive depends on the assumptions which impact Catalent Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTLT.

What is Catalent Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, CTLT's PE ratio (Price to Earnings) is -9.84 and Price to Sales (PS) ratio is 2.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTLT PE ratio will change depending on the future growth rate expectations of investors.